Mounjaro Pen Changes in April 2026 - What Patients Need to Know

Mounjaro Pen Changes in April 2026: What Patients Need to Know

From April 2026, patients in the UK may begin receiving an updated version of the Mounjaro® (tirzepatide) KwikPen. While the medication and dosing remain unchanged, the device itself has undergone important visual and structural improvements.

In this guide, we explain what’s changing, why it matters, and what you should expect.

What is changing with Mounjaro pens in 2026?

Eli Lilly will be introducing a visual and structural update to the Mounjaro
KwikPen.

The updated device has been modified to:

• Reduce leftover medicine
• Make it easier to track when the final dose has been administered
• Clearly indicate when the pen is ready to be discarded

Importantly, the modified KwikPen works in the same way as the original device.

When will the new Mounjaro pen be available?

The updated KwikPen is expected to become available in the UK from April 2026.

Existing stock of the current pen will continue to be dispensed

• Supply will gradually transition to the modified version
• Both versions will be available in the market during this period
• Patients may receive either version depending on pharmacy stock.

What stays the same?

Despite the design changes, the core treatment remains identical:

• Both versions are disposable, multi-dose, single-patient-use pre-filled pens
• Each pen delivers 4 fixed weekly doses (0.6mL per dose)
• The pen includes the necessary volume for priming before each injection
• The medication and dosing schedule are unchanged
• There is no difference in how the treatment works

Key updates to the new Mounjaro KwikPen

1. Improved plunger position

In the modified device:

• The plunger sits further down in the cartridge before first use
• This gives a clearer visual indication of remaining doses.

2. Extended internal plunger

A new internal component has been added behind the plunger, extending its length.

• This supports more accurate movement during dosing
• It improves visibility as doses are administered

3. Clearer end-of-pen indication

After the fourth dose:

• The plunger will sit near the end of the pen
• This clearly indicates the pen is ready to be discarded

This reduces confusion about whether doses remain.

4. Reduced leftover medication

The updated design reduces the amount of medicine remaining after the final dose.

This helps:

• Prevent misuse
• Improve dosing clarity
• Enhance patient safety

Will ordering or product codes change?

No.

• GTIN and PIP codes remain unchanged
• Pharmacies and providers can continue ordering as normal
• There is no administrative change required.

Why has the pen been updated?

The redesign focuses on:

✅ Improved clarity

Patients can more easily track dosing progress

✅ Better usability

The pen provides clearer visual feedback

✅ Enhanced safety

Reduced leftover medication lowers the risk of misuse

What should patients do?

If you receive the updated pen:

• Use it in the same way as your current device
• Continue following your prescribed dosing schedule
• Dispose of the pen after the fourth dose

If you are unsure, always speak to your pharmacist or prescribing clinician.

Pharmulous: Supporting you through treatment changes

At Pharmulous, we support patients with:

• GP-led online consultations
• Ongoing clinical guidance
• Safe, discreet home delivery

If you have questions about your treatment or device, our team is here to help.

Start your consultation

Visit: our Weight Loss Clinic

Access expert care, without the wait